Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting.

an inadequate response to biologics may reach 30% in psoriasis patients.1,2 In other inflammatory diseases, a positive effect of adding methotrexate (MTX) to adalimumab has been reported.3,4 In this real-world, Canadian multicenter, single-arm, phase IIIb, open-label study, sub-optimal responders who have been receiving adalimumab for ≥16 weeks, who had a Physician's Global Assessment (PGA) ≥ 3 and Psoriasis Area Severity Index (PASI) ≥ 5, continued to self-administer adalimumab (40 mg every other week). Oral MTX was added (10 to 25 mg per week as per investigator's decision and could vary throughout the length of study) as well as folic acid (1-mg tablet daily) for 24 weeks.